allow the sale of generic versions of Hospira 's ( HSP +1.4% ) sedative Precedex ..... injection) In its lawsuit filed yesterday, Hospira claims that the agency violated its own ..... intensive care unit sedation) covered by Hospira 's patent. In his order, Judge Jarrod
Aug 20 (Reuters) - A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.
Mylan ( MYL +1.3% ) launches dexmedetomidine hydrochoride injection, 100 mcg (base)/mL, the therapeutic equivalent of Hospira 's ( HSP -2.8% ) Precedex . The U.S. market is ~$156M. Mylan has 295 ANDAs pending FDA approval representing
(Adds details of Durbin letter, Wyden comment, background, byline)
WASHINGTON, Aug 14 (Reuters) - A senior U.S. senator said on Thursday he has written to the chief executive of Hospira Inc and urged the drug and medical device maker not to move its tax domicile...
Cubicin is facing a patent challenge from Hospira .If Cubist's CB-315/Surotomycin ..... news was a big win for Cubist, but Hospira has now also challenged the drug's patent. There is a risk that Hospira could prevail in litigation, and Cubicin
infusion pump sales surging 40%; the company should continue to benefit from ongoing market share gains as competitors like Hospira struggle with regulatory issues. The company has also made progress in the installation of its Pyxis ES system, which led
consent decree. A 2014 patent expiration on Hospira 's branded anesthetic Precedex and commencement ..... the company's profitability.Sales of Hospira 's medical devices should remain depressed ..... removed and hospital spending improves. Hospira is one of the first companies to successfully
dialysis drug payments), potential branded competition (Mircera as early as 2014), and biosimilar launches (including Hospira in 2016). For neutropenia drugs Neupogen and Neulasta, we see sales declining from $5.8 billion in 2013 to $4.3 billion
Hospira (NYSE: HSP ) Q2 2014 Earnings Call July 30, 2014 9:00 am ET Executives Karen King - F. Michael Ball - Chief Executive Officer